As Genfit deals and Conatus folds, Nash plays on
A China licensing deal from Genfit and the collapse of Conatus provide the latest news from the closely watched Nash space, which nervously awaits the next wave of…
Botox and the value of never-ending profits
Abbvie’s bid for Allergan shows that the Botox franchise is impenetrable. The market agrees.
Abbvergan by numbers
2019’s second mega-merger has emerged, and Vantage has crunched some EvaluatePharma data to help dissect the proposed deal.
A Botox filler for Abbvie's Humira-shaped hole
Abbvie’s swoop on Allergan looks like a case of opportunism over innovation.
Merck and the pitfalls of biopharma success
The developer of Keytruda is starting to look like a one-drug company; what must it do to avoid becoming the next Abbvie?
Novartis sees hidden value in Xiidra
Novartis will need to boost Xiidra sales to justify the hefty price it has paid, but the Swiss company has form.
Vistagen tries not to get depressed despite bad omens
A flop in a small depression trial hits Vistagen Therapeutics, but the group insists that all is well ahead of its main event.
Circassia averts its cash crunch
Payment of an overdue $120m Astrazeneca milestone, plus two other obligations, has been met through a loan facility with undisclosed terms.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.